Last reviewed · How we verify
Novavax recombinant protein vaccine
Novavax recombinant protein vaccine is a Recombinant protein vaccine Small molecule drug developed by Henry M. Jackson Foundation for the Advancement of Military Medicine. It is currently FDA-approved for COVID-19 prevention (marketed as Nuvaxovid), Respiratory syncytial virus (RSV) prevention (pipeline).
A recombinant protein vaccine that presents viral antigens to stimulate adaptive immune responses against infectious pathogens.
A recombinant protein vaccine that presents viral antigens to stimulate adaptive immune responses against infectious pathogens. Used for COVID-19 prevention (marketed as Nuvaxovid), Respiratory syncytial virus (RSV) prevention (pipeline).
At a glance
| Generic name | Novavax recombinant protein vaccine |
|---|---|
| Sponsor | Henry M. Jackson Foundation for the Advancement of Military Medicine |
| Drug class | Recombinant protein vaccine |
| Target | Viral surface antigens (e.g., SARS-CoV-2 spike protein) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Novavax vaccines use recombinant protein technology to produce viral antigens (such as spike proteins) that are combined with an adjuvant to enhance immunogenicity. These antigens are presented to the immune system to generate both antibody and T-cell mediated immune responses, providing protection against infection without using live virus or genetic material integration.
Approved indications
- COVID-19 prevention (marketed as Nuvaxovid)
- Respiratory syncytial virus (RSV) prevention (pipeline)
Common side effects
- Injection site pain
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
- COVID-19 Reactogenicity (PHASE4)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- COVID-19 Booster Study in Healthy Adults in Australia (PHASE3)
- Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study (PHASE4)
- COVID-19 Vaccines Safety Tracking (CoVaST)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novavax recombinant protein vaccine CI brief — competitive landscape report
- Novavax recombinant protein vaccine updates RSS · CI watch RSS
- Henry M. Jackson Foundation for the Advancement of Military Medicine portfolio CI
Frequently asked questions about Novavax recombinant protein vaccine
What is Novavax recombinant protein vaccine?
How does Novavax recombinant protein vaccine work?
What is Novavax recombinant protein vaccine used for?
Who makes Novavax recombinant protein vaccine?
What drug class is Novavax recombinant protein vaccine in?
What development phase is Novavax recombinant protein vaccine in?
What are the side effects of Novavax recombinant protein vaccine?
What does Novavax recombinant protein vaccine target?
Related
- Drug class: All Recombinant protein vaccine drugs
- Target: All drugs targeting Viral surface antigens (e.g., SARS-CoV-2 spike protein)
- Manufacturer: Henry M. Jackson Foundation for the Advancement of Military Medicine — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for COVID-19 prevention (marketed as Nuvaxovid)
- Indication: Drugs for Respiratory syncytial virus (RSV) prevention (pipeline)
- Compare: Novavax recombinant protein vaccine vs similar drugs
- Pricing: Novavax recombinant protein vaccine cost, discount & access